TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02647866
Drug: KHK4083
Normalized name: Anti-CD134 human monoclonal antibody (IgG1, KHK4083 dimer)
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion
Study: NCT03778671
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive Levobupivacaine 5%
Study: NCT03778671
Drug: Dexmedetomidine Injection [Precedex]
Normalized name: dexmedetomidine Injection [Precedex]
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive Levobupivacaine 5% + 1 µg/kg dexmedetomedine
Study: NCT01809223
Drug: conbercept, Fixed
DrugBank: Conbercept (DB12460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection of 0.5 mg conbercept per month, fixed injection
Study: NCT01809223
Drug: conbercept, PRN
DrugBank: Conbercept (DB12460)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravitreal injection of 0.5 mg conbercept as need, PRN
Study: NCT00430443
Drug: Liposomal Annamycin
Normalized name: Annamycin
DrugBank: Annamycin (DB06420)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-day IV infusion
Study: NCT06443827
Drug: Amantadine Sulfate
Normalized name: amantadine sulfate
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous amantadine sulphate at a single daily dose of 200 mg or physiological saline (0.9% NaCl solution)
Study: NCT02074514
Drug: Sofosbuvir
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg tablet administered orally once daily
Study: NCT02074514
Drug: RBV
Normalized name: RBV
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT00881608
Drug: Proellex
Normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
DrugBank: Telapristone acetate (DB05253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
Study: NCT02154334
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
Study: NCT04863105
Drug: Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)
DrugBank: Abiraterone (DB05812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study.
Study: NCT04386447
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to standard treatment, patients in the experimental arm will receive intravenous OT with dilution of 25 UI or 40 UI OT in 500cc physiological solution NaCl 9%. OT will be administered with continuous pump infusion with 62,5 ml/h. The clinician will have the option to decrease infusion speed based on significant variations in arterial pressure, otherwise, the total 25 UI or 40 UI amount will be infused in 8 hours. Treatment duration will be 10 days
Study: NCT01872962
Drug: gemcitabine and cisplatin (Induction chemotherapy)
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
Study: NCT03783065
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol was administrated orally while keeping monitoring heart rate and blood pressure daily.
Study: NCT01537172
Drug: ONO-4053
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
Study: NCT04046575
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Begins on day 1 of radiotherapy
Study: NCT04046575
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Begins on day 1 of radiotherapy
Study: NCT02084082
Drug: Linagliptin/Metformin ER FDC
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1x Linagliptin/Metformin FDC tablet
Study: NCT02084082
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1x Linagliptin tablet
Study: NCT02084082
Drug: Metformin ER
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2x Metformin ER tablets
Study: NCT02655653
Drug: Epsilon-aminocaproic acid administered
Normalized name: Epsilon Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Study: NCT02655653
Drug: Tranexamic Acid administered
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
Study: NCT00467766
Drug: Donepezil (Aricept)
Normalized name: donepezil Oral Tablet [Aricept]
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01740206
Drug: Amphetamine and/or methylphenidate
DrugBank: Amphetamine (DB00182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who took their stimulant medication the day of surgery.
Study: NCT00718601
Drug: Imetelstat Sodium (GRN163L)
Normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dose escalation infused over 2 hours weekly
Study: NCT00350545
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
Study: NCT00350545
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg; po per day with taper
Study: NCT00350545
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: trough 200-300 or lower; po
Study: NCT00350545
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trough 5-10 or lower; po
Study: NCT01794702
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
Study: NCT01794702
Drug: Idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
Study: NCT01794702
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
Study: NCT01794702
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)~Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion).
Study: NCT02154334
Drug: Mometasone
Normalized name: Mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
Study: NCT00775879
Drug: Induction with Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00434252
Drug: bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
Study: NCT00434252
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
Study: NCT00434252
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
Study: NCT00066456
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02733419
Drug: Enfuvirtide
Normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
Study: NCT02868944
Drug: experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03099785
Drug: Rifamycin SV 600mg t.i.d.
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
Study: NCT04323592
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual standard of care plus Methylprednisolone (MP) 80 mg/kg IV bolus, followed by MP infusion of 80 mg/day in 240 mL normal saline at 10 mL/h. The infusion is continued for at least eight days and until achieving either a PaO2:FiO2 \> 350 mmHg or a CRP \< 20 mg/L. Treatment is then switched to oral administration of Methylprednisolone 16 mg or 20 mg IV twice daily until CRP returns to \< 20% of normal range and/or PaO2:FiO2 \> 400 or SatHbO2 ≥ 95%. The decision to apply the protocol to Covid-19 is left to the discretion of the treating team for each individual patient.
Study: NCT00539396
Drug: Technosphere Insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02684084
Drug: Ozurdex
Normalized name: Ozurdex
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
Study: NCT02684084
Drug: Lucentis
Normalized name: Lucentis
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
Study: NCT02806895
Drug: JZP-110
Normalized name: JZP-386 free base
DrugBank: JZP-386 free base (DB17068)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01273558
Drug: Canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 100 mg capsule taken orally (by mouth) on Days Days 1-8
Study: NCT01615809
Drug: AMPHOTERICIN B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.
Study: NCT00618501
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01235585
Drug: bitopertin [RO4917838]
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose level 1, once a day for 52 weeks
Study: NCT01235585
Drug: bitopertin [RO4917838]
DrugBank: Bitopertin (DB12426)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT00618501
Drug: daunorubicin hydrochloride
Normalized name: Daunorubicin Hydrochloride
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00618501
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00618501
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00618501
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01067391
Drug: tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg tablet, administered once per study protocol
Study: NCT03276143
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg enoxaparin administered as subcutaneous injection once daily
Study: NCT03276143
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 2.5 mg apixaban administered as tablet orally twice daily
Study: NCT03034733
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
Study: NCT01700803
Drug: Povidone Iodine 10% vand cesarean section wound infections
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01700803
Drug: Povidone Iodine 7.5% vand cesarean section wound infections
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04287179
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose gradually increased over 12 weeks to 2.0 mg, followed by a 5 week maintenance period.
Study: NCT00958074
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT03034733
Drug: Sodium Chloride, (24)NaCl 0,9%
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous placebo
Study: NCT02606461
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 60mg
Study: NCT02556866
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
Study: NCT02556866
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01612013
Drug: Sodium bicarbonate plus saline
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT01612013
Drug: NAC plus sodium bicarbonate plus saline
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT01612013
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT01612013
Drug: NAC plus sodium bicarbonate plus saline
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
Study: NCT00338117
Drug: Galantamine hydrobromide
Normalized name: Galantamine Hydrobromide
DrugBank: Galantamine (DB00674)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01184872
Drug: Daptomycin
Normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.~Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days.
Study: NCT01184872
Drug: Vancomycin or Semi-Synthetic Penicillins (SSPs)
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.~Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days.
Study: NCT04714411
Drug: Omadacycline
Normalized name: omadacycline
DrugBank: Omadacycline (DB12455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omadacycline monotgherapy
Study: NCT03527264
Drug: Nivolumab induction
Normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 doses Nivolumab 240mg IV
Study: NCT03527264
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m2 of cisplatin: Dosing on Days: 1, 8, 15, 22, 29, 36 beginning on day 1 of radiation therapy.
Study: NCT03635788
Drug: Oral CAB
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAB 30 mg tablets
Study: NCT03635788
Drug: CAB-LA Loading Dose
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
Study: NCT01498874
Drug: gevokizumab
Normalized name: Gevokizumab
DrugBank: Gevokizumab (DB12119)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
Study: NCT03527264
Drug: Nivolumab with chemoradiation
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240mg IV every 14 days (+/- 3 days) for 3 doses, administered concomitantly during chemoradiation and beginning day 1 of Radiation.
Study: NCT03527264
Drug: Nivolumab maintenance
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 480 mg IV every 4 weeks for 2 years
Study: NCT00365417
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
Study: NCT00365417
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following clinical response assessment, 75 mg/m\^2 IV every 21 days x 4 cycles
Study: NCT00433836
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
Study: NCT00433836
Drug: Enalapril
Normalized name: Enalapril
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
Study: NCT01163799
Drug: Alefacept (ASP0485)
DrugBank: Alefacept (DB00092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
Study: NCT01702038
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mg administered intravenously